Volume 8, Supplement 7 (Dec 2017)

Continuing Education Information

A Letter From the Guest Editors

Chronic Lymphocytic Leukemia in 2018: What the Advanced Practitioner in Oncology Needs to Know

The clinical and scientific advances relative to chronic lymphocytic leukemia (CLL) over the last 5 years paint a picture of optimism. However, researchers, clinicians, patients and their caregivers will be challenged to not only continu...

Scientific Advances in the Diagnosis and Risk Stratification of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are a group of heterogeneous indolent B-cell malignancies that are largely incurable and occur most commonly in older adults. Chronic lymphocytic leukemia is the mos...

Monoclonal Antibodies in Chronic Lymphocytic Leukemia

Monoclonal antibodies that target CD20 and CD52 have been evaluated in the setting of chronic lymphocytic leukemia over the past 2 decades. Incorporating these agents into chemotherapy regimens has improved disease control, making chemoi...

Small Molecules in Chronic Lymphocytic Leukemia: Novel Targets, New Challenges

The treatment of chronic lymphocytic leukemia (CLL) is in a state of transformation owing largely to an improved understanding of the pathways and molecular targets in normal B-cell development, the role aberrant pathways play in the dev...

Emerging Therapies in Chronic Lymphocytic Leukemia: Current Trials

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults in the Western hemisphere, and in 2017, it is expected to be diagnosed in 20,110 people, with 4,660 dying of this disease. The median age at diagnosis of CLL is ...

Risk-Adapted Treatment Strategies for Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia among elderly patients. The disease can behave quite heterogeneously, as certain CLL patients will experience an indolent course, whereas others endure an agg...

Supportive Care and Management of Treatment-Emergent Adverse Events in Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, with 71 years as the median age at diagnosis. Many symptoms that patients with CLL experience are related to the disease but may also be associated with its treatment. Autoi...

The Older Adult Living With Chronic Lymphocytic Leukemia: Implications for Oncology Providers, Patients, and Caregivers

Chronic lymphocytic leukemia (CLL) is a disease most common in older adults, with a median age at diagnosis of 71 years. Chronic lymphocytic leukemia is considered an incurable but highly treatable disease, and it is characterized by var...

Appendix

Appendix. Treatment Regimens for Chronic Lymphocytic Leukemia